Moderna, Inc.
MRNA
$26.26
-$0.46-1.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -48.50% | -66.42% | 3.59% | -37.20% | -90.86% |
| Total Other Revenue | -- | 55.56% | -43.24% | 11.76% | -- |
| Total Revenue | -35.33% | -65.64% | 1.69% | -29.94% | -91.03% |
| Cost of Revenue | -18.38% | -20.30% | -51.46% | -28.90% | -39.73% |
| Gross Profit | 15.52% | -288.03% | 113.44% | 28.66% | -1,526.23% |
| SG&A Expenses | -22.63% | -25.32% | -36.43% | -19.28% | -10.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.19% | -21.14% | -49.73% | -27.45% | -35.68% |
| Operating Income | 17.06% | -20,866.67% | 96.52% | 27.00% | -245.90% |
| Income Before Tax | 17.25% | -1,791.43% | 101.07% | 26.87% | -281.97% |
| Income Tax Expenses | -30.00% | 56.46% | -99.52% | -- | 102.60% |
| Earnings from Continuing Operations | 17.36% | -616.13% | 100.36% | 7.32% | -1,587.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.36% | -616.13% | 100.36% | 7.32% | -1,587.34% |
| EBIT | 17.06% | -20,866.67% | 96.52% | 27.00% | -245.90% |
| EBITDA | 17.80% | -670.19% | 98.98% | 25.52% | -327.08% |
| EPS Basic | 18.22% | -610.73% | 100.35% | 8.04% | -1,602.64% |
| Normalized Basic EPS | 17.65% | -1,364.08% | 101.55% | 29.63% | -330.35% |
| EPS Diluted | 18.22% | -638.96% | 100.31% | 8.04% | -1,718.89% |
| Normalized Diluted EPS | 17.65% | -1,410.10% | 101.49% | 29.63% | -351.52% |
| Average Basic Shares Outstanding | 1.05% | 1.05% | 1.05% | 0.79% | -1.04% |
| Average Diluted Shares Outstanding | 1.05% | -2.53% | 4.72% | 0.79% | -5.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |